bwc0977
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 5, 2021 (NCT05088421)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Gyrase BINHIBITOR
Q6S6F1 inhibitor
- Topoisomerase IVINHIBITOR
Topoisomerase IV inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07029932 | Phase 1 | Oct 10, 2025 | Bugworks Research Inc., Nucleus Network Ltd |
| NCT05942820 | Phase 1 | Aug 30, 2023 | Avance Clinical Pty Ltd., Bugworks Research Inc. |
| NCT05088421 | Phase 1 | Nov 5, 2021 | Avance Clinical Pty Ltd., Bugworks Research Inc., CMAX Clinical Research |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bugworks Research Inc. | For profit | 3 | 3 | 1 | 2021 |
| Avance Clinical Pty Ltd. | For profit | 2 | 0 | 1 | 2021 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1